Transcode Therapeutics (RNAZ) Shares Outstanding (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Shares Outstanding (Entity) came in at $916968.0 in Q1 2026, up 432.37% YoY from $172241.0 in Q1 2025, and up 32.95% on a QoQ basis from $689713.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Shares Outstanding (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Shares Outstanding (Entity) data on file, last reported at $916968.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 432.37% year-over-year to $916968.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $916968.0 (up 432.37% YoY) and the FY2025 annual result came in at $689713.0, up 5323.55% from the prior year.
- Shares Outstanding (Entity) advanced to $916968.0 in Q1 2026, from $689713.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $916968.0 in Q1 2026 to a low of $18.0 in Q1 2022.
- A 5-year average of $205425.9 and a median of $6284.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) climbed 5.88% — and 2024, when it jumped 29823.81%.
- Tracing RNAZ's Shares Outstanding (Entity) over 5 years: stood at $18.0 in 2022, then surged by 977.78% to $194.0 in 2023, then surged by 6455.15% to $12717.0 in 2024, then jumped by 5323.55% to $689713.0 in 2025, then surged by 32.95% to $916968.0 in 2026.
- The last three Shares Outstanding (Entity) figures came in at $916968.0 (Q1 2026), $689713.0 (Q4 2025), and $833683.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 957,191.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 916,968.00 |
| Dec 31, 2025 | 689,713.00 |
| Sep 30, 2025 | 833,683.00 |
| Jun 30, 2025 | 833,654.00 |
| Mar 31, 2025 | 172,241.00 |
| Dec 31, 2024 | 12,717.00 |
| Sep 30, 2024 | 15,889.00 |
| Jun 30, 2024 | 7,629.00 |
| Mar 31, 2024 | 5,564.00 |
| Dec 31, 2023 | 194.00 |
| Sep 30, 2023 | 85.00 |
| Jun 30, 2023 | 36.00 |
| Mar 31, 2023 | 19.00 |
| Dec 31, 2022 | 18.00 |
| Sep 30, 2022 | 18.00 |
| Jun 30, 2022 | 18.00 |
| Mar 31, 2022 | 18.00 |
| Dec 31, 2021 | 11.00 |
| Sep 30, 2021 | 16.00 |
| Jun 30, 2021 | 6.00 |